Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
The Utility of a Methylation Panel in the Assessment of Clinical Response to Radiofrequency Ablation for Barrett's Esophagus
34 Pages Posted: 8 Jul 2020
More...Abstract
Background: Radiofrequency ablation (RFA) is an effective treatment for dysplastic Barrett’s esophagus (BE), but recurrence can occur after initial response. Currently there is uncertainty about how to best define histological remission. A DNA methylation panel on esophageal samples was previously shown to have high diagnostic accuracy for BE. We aimed to investigate this biomarker panel in the assessment of response to RFA treatment.
Methods: We retrospectively analyzed esophageal and gastroesophageal junction (GEJ) biopsies from patients with BE before and after RFA treatment. We quantified the extent of intestinal metaplasia (IM) based on number of glands with goblet cells (IM-Score) and expression of the intestinal factor trefoil factor-3 (TFF3-Score). Promoter methylation of 3 genes (ZNF345, TFP12, ZNF569) was measured by methylight (Meth-Score) throughout the RFA treatment pathway.
Findings: We included 45 patients (11 non-dysplastic BE, 14 low-grade dysplasia, 20 high-grade dysplasia/intramucosal cancer). Meth-Scores were significantly higher in BE with and without dysplasia and GEJ with IM compared to GEJ without IM (P <·001). Meth-scores significantly correlated with the extent of IM at the GEJ measured both with IM-Scores (rho=66·0%, P<·001), and TFF3-Scores (rho=75·6%, P<·001). In patients with residual IM at the GEJ, RFA re-treatment brought about a 7·6-fold reduction in the methylation levels. The Meth-score had an area under the ROC curve of 95·1% (95%CI 91·1% - 99·1%) differentiating BE from normal GEJ.
Interpretation: A DNA methylation panel can discriminate between the extent of histological IM in esophageal and junctional biopsies and could be used to objectively quantify residual disease following RFA.
Funding Statement: This study was funded by a Medical Research Council core grant to RCF. WJ was funded by a Cancer Research UK multidisciplinary award (C47594/A21202). We would like to acknowledge clinical research infrastructure support from the Experimental Cancer Medicine Centre and the Cambridge Biomedical Research Centre. The funding bodies had no role in study design, patient recruitment, data collection, data analysis, data interpretation, writing of the manuscript or any other aspect pertinent to the study.
Declaration of Interests: All of the authors disclose no conflict of interest.
Ethics Approval Statement: The study was approved by the ethics committee at the local institution (LREC01/149). Informed consent for biomarker analysis was obtained from each patient before endoscopic treatment.
Keywords: Oesophageal cancer; Biomarkers; Methylation; Endoscopic Therapy, Intestinal Metaplasia
Suggested Citation: Suggested Citation